Dr. Nayak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-2166Fax+1 617-632-4773- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 2006 - 2009
New York Downtown HospitalResidency, Internal Medicine, 2004 - 2006
Grant Medical CollegeClass of 2002
Certifications & Licensure
ME State Medical License Current
FL State Medical License 2022 - Present
MA State Medical License 2011 - 2026
NY State Medical License 2011 - 2013
PA State Medical License 2009 - 2010- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
- TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Start of enrollment: 2014 May 20
- Pembrolizumab, Ibrutinib and Rituximab in PCNSL Start of enrollment: 2020 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.Lauren Schaff, Lakshmi Nayak, Christian Grommes> ;Leukemia & Lymphoma. 2024 Apr 10
- Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.Kim, A., Lou, K., Giobbie-Hurder, A., Chang, K., Gidwani, M., Hoebel, K., Patel, J., Cleveland, M., Singh, P., Bridge, C., Ahmed, S., Bearce, B., Liu, W., Fuster-Garci...> ;Neuro-Oncology. 2023 Dec 9
- 1 citationsEvidence-based management of primary and secondary CNS lymphoma.Khwaja, J., Cwynarski, K., Nayak, L.> ;Seminars in Hematology. 2023 Nov 1
- Join now to see all
Lectures
- Turning the Corner in Relapsed/Refractory CNS Lymphoma: Applying Precision and Immune-Based...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with r...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Kazia Enters Clinical Collaboration with Dana-Farber Cancer Institute for Primary CNS LymphomaSeptember 22nd, 2020
The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in FundingNovember 8th, 2018
Immunotherapy Agent Yields Full and Partial Remissions in Aggressive Non-Hodgkin LymphomasDecember 5th, 2016
Professional Memberships
- Member
- Member
Hospital Affiliations
Brigham and Women's HospitalBoston, Massachusetts
Salem HospitalSalem, Massachusetts
Dana-Farber Cancer InstituteBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
